PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.
PP405 is a promising molecule that may reactivate dormant hairfollicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
Hairfollicles usually go dormant rather than die, and treatments like finasteride, minoxidil, and hormone therapy can sometimes reactivate them, though results vary. Complete regrowth is rare, especially in long-term bald areas, but some individuals see significant improvement with these treatments.
PP405 shows promise for reactivating hairfollicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hairfollicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.